U.S. markets close in 1 hour 58 minutes
  • S&P 500

    3,847.26
    -23.03 (-0.60%)
     
  • Dow 30

    31,472.13
    +80.61 (+0.26%)
     
  • Nasdaq

    13,096.04
    -262.75 (-1.97%)
     
  • Russell 2000

    2,240.74
    +9.23 (+0.41%)
     
  • Crude Oil

    61.63
    +1.88 (+3.15%)
     
  • Gold

    1,718.00
    -15.60 (-0.90%)
     
  • Silver

    26.40
    -0.48 (-1.78%)
     
  • EUR/USD

    1.2076
    -0.0012 (-0.10%)
     
  • 10-Yr Bond

    1.4720
    +0.0570 (+4.03%)
     
  • GBP/USD

    1.3971
    +0.0015 (+0.11%)
     
  • USD/JPY

    106.9450
    +0.2350 (+0.22%)
     
  • BTC-USD

    51,235.84
    +3,295.61 (+6.87%)
     
  • CMC Crypto 200

    1,025.98
    +37.88 (+3.83%)
     
  • FTSE 100

    6,675.47
    +61.72 (+0.93%)
     
  • Nikkei 225

    29,559.10
    +150.93 (+0.51%)
     

Pfizer (PFE) Gains As Market Dips: What You Should Know

  • Oops!
    Something went wrong.
    Please try again later.
Zacks Equity Research
·2 min read
  • Oops!
    Something went wrong.
    Please try again later.

Pfizer (PFE) closed the most recent trading day at $37.31, moving +0.08% from the previous trading session. This change outpaced the S&P 500's 0.15% loss on the day. Meanwhile, the Dow lost 0.07%, and the Nasdaq, a tech-heavy index, lost 0.07%.

Investors will be hoping for strength from PFE as it approaches its next earnings release, which is expected to be February 2, 2021. In that report, analysts expect PFE to post earnings of $0.50 per share. This would mark a year-over-year decline of 9.09%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $12.85 billion, up 1.25% from the year-ago period.

Investors might also notice recent changes to analyst estimates for PFE. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.

Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.

The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 6.05% lower. PFE is currently a Zacks Rank #3 (Hold).

Digging into valuation, PFE currently has a Forward P/E ratio of 11.2. Its industry sports an average Forward P/E of 14.12, so we one might conclude that PFE is trading at a discount comparatively.

We can also see that PFE currently has a PEG ratio of 2.81. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Large Cap Pharmaceuticals was holding an average PEG ratio of 2.09 at yesterday's closing price.

The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 198, which puts it in the bottom 23% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

To follow PFE in the coming trading sessions, be sure to utilize Zacks.com.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Pfizer Inc. (PFE) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research